µå·¯±×ÀÎÆ÷¸ÞÀÎ
 

»óº´Äڵ忡 µû¸¥ »óº´¸íÀ» È®ÀÎ ÇϽǼö ÀÖ½À´Ï´Ù.  
»óº´ÄÚµå ÇÑ±Û»óº´¸í ¿µ¹®»óº´¸í
Y541 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¤ÁúÄÚƼÄÚÀÌµå ±æÇ×Á¦[¾Ëµµ½ºÅ׷бæÇ×Á¦] Mineralocorticoid antagonists [aldosterone antagonists] causing adverse effects in therapeutic use
Y542 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ź»ê¾ÈÈ÷µå¶ó¾ïÁ¦Á¦ Carbonic-anhydrase inhibitors causing adverse effects in therapeutic use
Y542 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾Æ¼¼Å¸Á¹¾Æ¹Ìµå Acetazolamide causing adverse effects in therapeutic use
Y543 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â º¥Á¶Æ¼¾Æµð¾ÆÁø À¯µµÃ¼ Benzothiadiazine derivatives causing adverse effects in therapeutic use
Y544 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â [°í¸®]ÀÌ´¢Á¦ Loop [High-ceiling] diuretics causing adverse effects in therapeutic use
Y545 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âŸ ÀÌ´¢Á¦ Other diuretics causing adverse effects in therapeutic use
Y546 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀüÇØÁú, Ä®·Î¸® ¹× ¼öºÐÆòÇü Á¦Á¦ Electrolytic, caloric and water-balance agents causing adverse effects in therapeutic use
Y546 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¸°­ Àç¼öÈ­¿°·ù Oral rehydration salts causing adverse effects in therapeutic use
Y547 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¼®È¸È­¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ Agents affecting calcification causing adverse effects in therapeutic use
Y547 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºÎ°©»ó¼± È£¸£¸ó ¹× À¯µµÃ¼ Parathyroid hormones and derivatives causing adverse effects in therapeutic use
Y547 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ºñŸ¹Î D ±º Vitamin D group causing adverse effects in therapeutic use
Y548 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¿ä»ê´ë»ç¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ Agents affecting uric acid metabolism causing adverse effects in therapeutic use
Y549 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¹«±â¿°·ù Mineral salts, NEC causing adverse effects in therapeutic use
Y55 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ÆòÈ°±Ù ¹× °ñ°Ý±Ù°ú È£Èí°èÅë¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ Agents primarily acting on smooth and skeletal muscles and the respiratory system causing adverse effects in therapeutic use
Y550 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀڱüöÃ༺ ¾à¹° Oxytocic drugs causing adverse effects in therapeutic use
Y550 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸Æ°¢¾ËÄ®·ÎÀ̵å Ergot alkaloids causing adverse effects in therapeutic use
Y551 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °ñ°Ý±ÙÀÌ¿ÏÁ¦[½Å°æ±ÙÀ° Â÷´ÜÁ¦] Skeletal muscle relaxants [neuromusclular blocking agents]causing adverse effects in therapeutic use
Y552 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ±ÙÀ°¿¡ ÀÛ¿ëÇÏ´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Á¦Á¦ Other and unspecified agents primarily acting on muscles causing adverse effects in therapeutic use
Y553 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âħ¾à Antitussives causing adverse effects in therapeutic use
Y554 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °¡·¡¾à Expectorants causing adverse effects in therapeutic use
3881  [3882] 3883  3884  3885  3886  3887  3888  3889  3890